Clinical Development of Orphan Drugs 2015

A unique opportunity to build new relationships and improve existing partnerships between industry and patient organisations

Clarifying Regulations for Orphan Drugs with case-studies & recommendations to help you overcome common pitfalls in adhering to drug development regulations

Benchmark your orphan drug development programme against leading players such as Pfizer, GSK, Roche & NPS Pharma

Overcome challenges and gain solutions for small populations, critical considerations for trial design & strategies to boost patient enrollment & retention

Improve partnerships with patient organisations with critical recommendations for effective partnering

Get the most from your joint HTA/EMA meeting with critical insight and first-hand advice from NICE

Understand off-label use and its implications for product approval

Arrange one-to-one meetings with key stakeholders via EBD’s partnering system, groupsPLUS